๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Neoadjuvant Therapy
Clinical trial register · China

Neoadjuvant Therapy Trials in China, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Shanghai 13 Beijing 13 Hangzhou 10 Guangzhou 9 Nanjing 5
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Fudan University6 Sun Yat-sen University6 Second Affiliated Hospital, Zhejiang University, School of Medicine5 Peking University People's Hospital3 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology3
Site location
Shanghai13 Beijing13 Hangzhou10 Guangzhou9 Nanjing5
All 24 locations
Target enrolment
to

Neoadjuvant Therapy trials in China

74 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
By invitation
Adaptive Neoadjuvant Therapy for Esophageal Cancer
NCT06990178Esophageal Carcinoma, Neoadjuvant Therapy
Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center
Not applicable
43
Shenzhen
2028-03-01
Not yet open
Neoadjuvant Therapy With Firmonertinib Combined With Anlotinib and Platinum-Based Doublet Chemotherapy for Resectable EGFR-Mutated NSCLC
NCT07807722NSCLC (Non-small Cell Lung Cancer), EGFR, Neoadjuvant Therapy
Hubei Cancer Hospital
Phase 2
29
Wuhan
2026-09-21
Not yet open
Neoadjuvant Presurgical Becotatug Vedotin (MRG003) Plus Pucotenlimab (HX008) in Oral Cavity Squamous Cell Carcinoma
NCT07766889Oral Squamous Cell Carcinoma, Head and Neck Cancer, Locally Advanced Head and Neck Cancer, Neoadjuvant Therapy
Sun Yat-sen University
Phase 2
32
Guangzhou
2026-09-01
Not yet open
Neoadjuvant Disitamab Vedotin, Toripalimab, and Radiotherapy for High-risk UTUC ( LUXUS07.1 )
NCT07720921Urothelial Carcinoma of the Renal Pelvis and Ureter, Neoadjuvant Therapy
Peking University First Hospital
Phase 2
20
Beijing
2026-08-01
Not yet open
Neoadjuvant Ivonescimab๏ผˆAK112๏ผ‰ Combined With Chemotherapy in Patients With Resectable Esophageal Squamous Cell Carcinoma
NCT07244978Esophageal Squamous Cell Carcinoma, Neoadjuvant Therapy
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
49
Hangzhou
2026-06-01
Recruiting
Olaparib+Trastuzumab+Pertuzumab Neoadjuvant for Elderly HER2+ Breast Cancer
NCT07695259Elderly Females, HER2 + Breast Cancer, Neoadjuvant Therapy
Wen-Ming Cao
Phase 4
45
Hangzhou
2026-05-25
Not yet open
Camrelizumab, Chemotherapy and Ivarmacitinib in Patients With Resectable Esophageal Squamous Cell Carcinoma
NCT07505186Esophageal Squamous Cell Carcinoma, Neoadjuvant Therapy
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
45
Hangzhou
2026-05-01
Recruiting
Nimotuzumab Combined With Immunotherapy and Chemotherapy in the Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma
NCT07601737Head and Neck Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma (HNSCC), Head & Neck Cancer, Neoadjuvant Therapy
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Phase 2
182
Shanghai
2026-04-20
Not yet open
Neoadjuvant Therapy for Early Triple-Negative Breast Cancer: A Response-Guided Approach Using Iparomlimab and Tuvonralimab Injection in Combination With Chemotherapy
NCT07372079Breast Cancer, Neoadjuvant Therapy, Immune Checkpoint Inhibitors, QL1706
Tianjin Medical University Cancer Institute and Hospital
Phase 2
40
Tianjin
2026-04-05
Recruiting
Digital Mind-Body Therapy for Neoadjuvant Breast Cancer
NCT07541664Neoadjuvant Therapy
Fudan University
Not applicable
66
Shanghai
2026-03-25
Recruiting
Interferon Gamma Plus Camrelizumab as Neoadjuvant Therapy for Locally Advanced Esophageal Squamous Cell Carcinoma
NCT07787273Locally Advanced Esophageal Squamous Cell Carcinoma, Neoadjuvant Therapy, Camrelizumab
Hefei Cancer Hospital of the Chinese Academy of Sciences
Phase 2
84
Hefei
2026-03-20
Recruiting
Neoadjuvant Chemoradiotherapy Plus Tislelizumab With or Without Probio-M9 in pMMR/MSS Locally Advanced Rectal Cancer
NCT07458529Rectal Cancer, Adenocarcinoma, Neoadjuvant Therapy, Immunotherapy, Probio-M9
Seventh Medical Center of PLA General Hospital
Phase 2
50
Beijing
2026-02-10
Recruiting
Fulzerasib Sequential Sintilimab Plus Platinum-Doublet Neoadjuvant Therapy for Resectable KRAS G12C-Mutant NSCLC
NCT07492342Resectable NSCLC, KRAS G12C Mutation, Stage IB-IIIA NSCLC, Neoadjuvant Therapy
Jianxing He
Phase 2
30
Beijing, Guangzhou, Zhejiang
2026-01-29
Recruiting
Sintilimab Plus Bevacizumab Biosimilar as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma
NCT07324824Hepatocellular Carcinoma, Neoadjuvant Therapy, Sintilimab, Bevacizimab
Sun Yat-sen University
Phase 2
37
Guangzhou
2026-01-14
Recruiting
Prediction of Outcome to Neoadjuvant Therapy in Non-small Cell Lung Cancer๏ผˆNSCLC๏ผ‰
NCT07388771NSCLC, Neoadjuvant Therapy
Qian Chu
Observational
500
Wuhan, Hangzhou
2025-12-01
Not yet open
Adebrelimab Combined With Chemotherapy for Neoadjuvant Therapy in Resectable Pancreatic Cancer
NCT06177522Pancreatic Cancer, Neoadjuvant Therapy
Jinling Hospital, China
Phase 2
30
Nanjing
2025-11-30
Recruiting
Iparomlimab and Tuvonralimab (QL1706) Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC
NCT07389629Iparomlimab and Tuvonralimab, Clear Cell Renal Cell Carcinoma, Neoadjuvant Therapy
Sun Yat-sen University
Phase 2
25
Guangzhou
2025-11-21
Not yet open
A Prospective, Single-center, Phase II Study of Sacituzumab Tirumotecan in Combination With Pembrolizumab for Neoadjuvant Treatment of Triple-Negative Breast Cancer (TNBC)
NCT07054242Neoadjuvant Therapy, Stage II to III (T1cN1-2 or T2-4N0-2) TNBC Breast Cancer
Yantai Yuhuangding Hospital
Phase 2
52
Yantai
2025-10-30
Not yet open
Neoadjuvant CAPOX Plus Tislelizumab vs CAPOX in MSS High-Risk Locally Advanced Colon Cancer
NCT07132008Colonic Neoplasms, Neoadjuvant Therapy, Immune Checkpoint Inhibitors
First Affiliated Hospital of Guangxi Medical University
Phase 3
94
Nanning
2025-10-01
Not yet open
Vebreltinib for Neoadjuvant in METex 14 Skipping Mutant Stage IIA-IIIB (N2) Non-small Cell Lung Cancer (NSCLC)
NCT07156604NSCLC, Neoadjuvant Therapy
Fudan University
Phase 2
30
Shanghai
2025-09-30
Not yet open
Family-Supervised Prehabilitation to Reduce Postoperative Complications After Neoadjuvant Chemotherapy in Gastric Cancer
NCT07183358Stomach Neoplasms, Neoadjuvant Therapy
The Affiliated Hospital of Qingdao University
Not applicable
90
Qingdao
2025-09-20
Not yet open
Simple Surgical Glove Compression to Prevent Chemotherapy-Induced Peripheral Neuropathy
NCT07169864Breast Cancer, Chemotherapy Induced Peripheral Neuropathy (CIPN), Neoadjuvant Therapy
Jinsong Lu
Not applicable
44
Shanghai
2025-09-15
Recruiting
Sleeve Lobectomy Following Neoadjuvant Therapy in NSCLC
NCT07135856Lung Cancer, Neoadjuvant Therapy
Shanghai Chest Hospital
Observational
400
Shanghai
2025-09-01
Recruiting
Long-course Chemoradiotherapy or Short-course Radiotherapy Combined With CAPOX, PD-1antibody, and COX-2 Inhibitor for MSS Locally Advanced Rectal Cancer (SERRAC)
NCT07150949Locally Advanced Rectal Cancer, Neoadjuvant Therapy
Fudan University
Phase 2
138
Shanghai
2025-08-28
Not yet open
Envafolimab Combined With Neoadjuvant Chemotherapy Treat Stage IIb Resectable Osteosarcoma Patients
NCT07142863Osteosarcoma, Neoadjuvant Therapy, Neoadjuvant Chemotherapy, PD-L1 Antibody
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Phase 2
23
Shanghai
2025-08-25
Active, closed
Neoadjuvant Chemotherapy Before Surgery vs Surgery Alone for UTUC: A Randomized Trial
NCT07492225Neoadjuvant Therapy, Urothelial Carcinoma Ureter, Upper Urinary Tract Urothelial Carcinoma
Changhai Hospital
Phase 2
120
Shanghai
2025-08-15
Not yet open
A Phase II Randomized Trial of Neoadjuvant Ivonescimab or Penpulimab Plus Chemotherapy in Resectable NSCLC
NCT07086326NSCLC, Neoadjuvant Therapy, Immunotherapy, AK112
Yang Fan, MD
Phase 2
164
Beijing, Changsha, Shanghai, Xiโ€™an, Hangzhou
2025-07-31
Recruiting
Neoadjuvant Radiotherapy Plus Tegafur, Oxaliplatin and Iparomlimab and Tuvonralimab in Resectable Gastric and GE-junction Cancer : A Randomized, Two-arm, Prospective Trial (TRIUNITE-05)
NCT07165847Immunotherapy, Gastric Cancer (GC), Radiotherapy, Neoadjuvant Therapy
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Phase 2
40
Chongqing
2025-07-23
By invitation
Paclitaxel Polymeric Micelles and Carboplatin in Combination With Iparomilimab and Tuvonralimab Neoadjuvant Therapy for Triple-negative Breast Cancer๏ผˆUPGRADE-TNBC๏ผ‰
NCT06910072Triple-Negative Breast Cancer (TNBC), Neoadjuvant Therapy
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2/3
32
Beijing
2025-07-21
Recruiting
Pucotenlimab Combination With Vorolanib as Neoadjuvant Therapy for ccRCC
NCT07386158Vorolanib, Clear Cell Renal Cell Carcinoma (ccRCC), Neoadjuvant Therapy
Sun Yat-sen University
Phase 2
21
Guangzhou
2025-07-10
Recruiting
Neoadjuvant Tislelizumab + Nab-Paclitaxel Followed by Distal Ureterectomy for Ureteral Cancer
NCT07125547Ureteral Cancer, Neoadjuvant Therapy, PD-1 Inhibitor, Kidney-sparing
Tianjin Medical University Second Hospital
Phase 2
35
Tianjin
2025-07-05
Recruiting
Neoadjuvant Tislelizumab in Combination With Nab-Paclitaxel for UTUC
NCT07126119Upper Tract Urothelial Carcinoma, Neoadjuvant Therapy, PD-1 Inhibitor, Nab-paclitaxel
Tianjin Medical University Second Hospital
Phase 2
35
Tianjin
2025-07-05
Recruiting
Mechanism of Enhanced Efficacy of Ivonescimab in Neoadjuvant Therapy for Non-Small Cell Lung Cancer
NCT07359040Non-Small Cell Lung Cancer, Neoadjuvant Therapy, PD-1 Inhibitors, Immunotherapy
Peking University People's Hospital
Observational
80
Beijing
2025-07-01
Not yet open
Benmelstobart-Anlotinib-Chemo for Neoadjuvant Oral Cancer
NCT06848439Mouth Neoplasms, Neoadjuvant Therapy, Immunotherapy, Molecular Targeted Therapy
Jiangsu Cancer Institute & Hospital
Phase 2
26
Nanjing
2025-06-15
Active, closed
A Clinical Trial of Neoadjuvant Targeted Therapy, Immunotherapy, and Lysogenic HSV-Based Virotherapy in Resectable Head and Neck Squamous Cell Carcinoma
NCT07010120HNSCC, Lysogenic HSV Virus, Neoadjuvant Therapy, Immunotherapy
West China Hospital
Phase 1/2
29
Chengdu
2025-06-10
Recruiting
FAP-targeted PET/NIR in Lung Malignant Tumors
NCT07498933Non-Small Cell Lung Cancer, PET/CT, Neoadjuvant Therapy
Peking University People's Hospital
Observational
200
Beijing
2025-06-03
Recruiting
Neoadjuvant Cadonilimab Combined With Perioperative Oxaliplatin Plus S1 for Diffuse or Mixed Type of Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
NCT06949033Gastric Cancer (Including Stomach and Gastroesophageal Junction [GEJ]), Neoadjuvant Therapy, Adjuvant Chemotherapy, pCR Rate
Zuoyi Jiao
Phase 3
668
Lanzhou
2025-05-15
Recruiting
To Conduct Multi-omics Integrated Studies in Peripheral Blood, Such as Fragment Omics, Metabolomics and Epigenetics, and Establish Non-invasive Dynamic Follow-up Monitoring Programs During Perioperative and Postoperative Periods (Observational Study)
NCT07291921Lung Neoplasms, Neoadjuvant Therapy, Immunotherapy, Minimal Residual Disease
Peking University People's Hospital
Observational
100
Beijing
2025-05-08
Recruiting
Using 4D Urinary Proteomics to Predict and Evaluate Treatment Response in Colorectal Cancer
NCT06904677Colorectal Cancer (CRC), Neoadjuvant Therapy, Proteomics
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Observational
400
Beijing
2025-05-01
Recruiting
A Clinical Study on the Efficacy and Safety of Paclitaxel Polymeric Micelles and Cisplatin Combined With Cadonilimab as a Neoadjuvant Therapy for Locally Advanced Esophageal Squamous Cell Carcinoma
NCT06356688Locally Advanced Esophageal Squamous Cell Carcinoma, Neoadjuvant Therapy
Sun Jing
Phase 2
30
Nanjing
2025-04-20
Recruiting
Neoadjuvant Apatinib Combined With Sintilimab and Perioperative SOX Versus Neoadjuvant Sintilimab Combined With Perioperative SOX for Intestinal Type of Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
NCT06925243Gastric Cancer (Including Stomach and Gastroesophageal Junction [GEJ]), Neoadjuvant Therapy, Adjuvant Chemotherapy, pCR Rate
Zuoyi Jiao
Phase 3
682
Lanzhou
2025-04-15
Recruiting
Neoadjuvant SNF Precision Therapy Phase III
NCT06913777Neoadjuvant Therapy
Fudan University
Phase 3
404
Shanghai
2025-04-08
Not yet open
Study of Sinibolimab Combined with Lenvatinib As Neoadjuvant Therapy for Locally Advanced Unresectable Differentiated Thyroid Carcinoma
NCT06848920Differentiated Thyroid Carcinoma (DTC), Neoadjuvant Therapy
Zhejiang University
Phase 2
20
Hangzhou
2025-03-01
Not yet open
Efficacy and Safety of Ensartinib in Neoadjuvant Therapy for Stage IIA - IIIB (Operable or Potentially Operable) ALK-Positive Lung Adenocarcinoma ๏ผšA Multicenter, Real-World Clinical Study
NCT06785584ALK-positive Advanced NSCLC, ALK-positive Non-small Cell Lung Cancer (NSCLC), MPR, Neoadjuvant Therapy
Fujian Medical University Union Hospital
Phase 4
30
Fuzhou
2025-02-01
Active, closed
Predictive Value of Tumor Vascular Normalization Scoring in HER-2 Positive Breast Cancer
NCT06868758HER2 Positive Breast Carcinoma, Neoadjuvant Therapy
Chongqing General Hospital
Observational
50
Chongqing
2025-01-01
Recruiting
Exploring the Treatment Duration of PD-1 Neoadjuvant Therapy in Stage II-III dMMR Rectal Cancer
NCT06613165Immune-related Adverse Event, Neoadjuvant Therapy, dMMR Colorectal Cancer
Xijing Hospital
Observational
100
Xi'an
2025-01-01
Recruiting
Application of MRI Radiomics Features in Neoadjuvant Therapy of Head and Neck Squamous Cell Carcinoma
NCT06755567Head and Neck Cancer, Neoadjuvant Therapy, Immunotherapy, Chemotherapy
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Observational
750
Guangzhou
2024-12-25
Recruiting
A Clinical Study on Neoadjuvant Treatment of Resectable Head and Neck Squamous Carcinoma With Immune-targeted Therapy and Lysogenic HSV Virus
NCT06741982HNSCC, Lysogenic HSV Virus, Neoadjuvant Therapy, Immunotherapy
West China Hospital
Phase 1
21
Chengdu
2024-12-15
Active, closed
Application of Targeted Axillary Lymph Node Resection in Axillary Surgery After Neoadjuvant Chemotherapy for Breast Cancer: an Open-label, Multicenter Study
NCT07032220Breast Cancer Surgery, Neoadjuvant Therapy, Sentinel Lymph Node Biopsy (SLNB)
Fujian Medical University Union Hospital
Not applicable
175
Fuzhou
2024-12-09
Not yet open
Neoadjuvant Therapy of Targeted Immunotherapy Combined With Chemotherapy for Locally Advanced HNSCC
NCT06699498Head and Neck Squamous Cell Carcinoma, Neoadjuvant Therapy, PD-L1, Anlotinib
The First Affiliated Hospital with Nanjing Medical University
Phase 2
45
Nanjing
2024-12-03
Recruiting
Neoadjuvant Chemotherapy Plus Pyrotinib and Trastuzumab for HER2-positive Breast Cancer (NEOTORCH-BREAST05)
NCT06832904HER2-positive Breast Cancer, Neoadjuvant Therapy, Pyrotinib
First Affiliated Hospital of Zhejiang University
Phase 2
33
Hangzhou
2024-12-03
Recruiting
Neoadjuvant Immunotherapy Plus Chemotherapy Followed by Concurrent Chemoradiotherapy and Consolidative Immunotherapy for Locally Advanced Non-small Cell Lung Cancer
NCT06734702Neoadjuvant Therapy, Concurrent Chemoradiotherapy, Immunotherapy, Locally Advanced Non-Small Cell Lung Cancer
Sun Yat-sen University
Phase 3
497
Guangzhou
2024-11-30
Recruiting
Effect of Vitamin D Supplementation on the Efficacy and Adverse Effects of Neoadjuvant Therapy in Patients with Breast Cancer
NCT06642428Vitamin D, Neoadjuvant Therapy, Breast Cancer, Adverse Reaction
Jiuda Zhao
Not applicable
140
Xining
2024-10-18
Recruiting
Short-course Radiotherapy Followed by AK112 and CAPOX as Neoadjuvant Therapy for Locally Advanced Rectal Cancer
NCT06802666Locally Advanced Rectal Cancer, Neoadjuvant Therapy
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2
45
Hubei
2024-10-16
Not yet open
QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk TNBC Breast Cancer
NCT06404736Early Breast Cancer, Neoadjuvant Therapy, TNBC, Triple Negative Breast Cancer
Fudan University
Phase 2
73
Shanghai
2024-05-07
Recruiting
CAPOX and PD-1 Antibody Combined With or Without Radiotherapy for MSS Locally Advanced Rectal Cancer
NCT06281405Locally Advanced Rectal Cancer, Neoadjuvant Therapy
Fudan University
Phase 2
192
Shanghai
2024-03-28
Recruiting
A Study of Neoadjuvant Therapy for the Treatment of Patients With Locally Advanced Esophageal Squamous Cell Carcinoma
NCT06354530Neoadjuvant Therapy, Esophageal Squamous Cell Carcinoma
Army Medical Center of PLA
Phase 2/3
266
Chongqing
2024-03-08
Recruiting
Efficacy and Safety of Neoadjuvant Envafolimab Combined With Albumin-bound Paclitaxel and Carboplatin for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
NCT07266493Esophageal Squamous Cell Carcinoma, Neoadjuvant Therapy
Shanghai Zhongshan Hospital
Phase 2
26
Shanghai
2023-12-01
Active, closed
Neoadjuvant Tislelizumab With Chemotherapy for the Treatment of MSS Colon Cancer
NCT06124378Colonic Neoplasms, Neoadjuvant Therapy, Immune Checkpoint Inhibitors
First Affiliated Hospital of Guangxi Medical University
Phase 2
60
Nanning
2023-11-13
Not yet open
Neoadjuvant PD-1 Inhibitor Combined With Cetuximab in Operable Locally Advanced HNSCC
NCT05993858Head and Neck Squamous Cell Carcinoma, Neoadjuvant Therapy
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2
33
Wuhan
2023-10-20
Not yet open
Study of Utidelone Based Neoadjuvant Treatment on Early High-risk or Locally Advanced Breast Cancer
NCT05983094Breast Cancer, Neoadjuvant Therapy
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
181
Beijing
2023-09-01
Active, closed
Serplulimab Combined With Chemotherapy in Patients With Resectable Non-small-cell Lung Cancer
NCT05882513NSCLC, Neoadjuvant Therapy
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
36
Hangzhou
2023-05-16
Recruiting
Evaluating the Efficacy and Safety of Pembrolizumab Plus Standard Chemotherapy in the Neoadjuvant Treatment of Local Advanced (LA) HNSCC
NCT06102395Head and Neck Squamous Cell Carcinoma, Neoadjuvant Therapy, Pembrolizumab
Beijing Tongren Hospital
Phase 3
272
Beijing
2023-05-01
Recruiting
Neoadjuvant Camrelizumab Combined With Chemotherapy for Resectable Stage IIIA-IIIB NSCLC
NCT06241807IMMUNOTHERAPY, Neoadjuvant Therapy, Resectable Lung Non-Small Cell Carcinoma, Biomarkers / Blood
Shandong Cancer Hospital and Institute
Phase 2
30
Jinan
2022-12-02
Active, closed
Serplulimab Combined With Chemotherapy in Patients With Resectable Esophageal Squamous Cell Carcinoma
NCT05659251Esophageal Squamous Cell Carcinoma, Neoadjuvant Therapy
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
48
Hangzhou
2022-12-01
Active, closed
PD-1 Inhibitor Plus GP as Neoadjuvant Therapy for Locoregionally Advanced Nasopharyngeal Carcinoma
NCT05340270Nasopharyngeal Carcinoma, Neoadjuvant Therapy, PD-1 Inhibitor
Guangxi Medical University
Phase 2
150
Nanning
2022-07-15
Active, closed
Neoadjuvant/Adjuvant Pembrolizumab Plus Chemotherapy
NCT05383716Non Small Cell Lung Cancer, Neoadjuvant Therapy, Immune Checkpoint Inhibitor
Peking Union Medical College Hospital
Phase 2
80
Beijing
2022-07-01
Active, closed
Reducing Excision Margins After Neoadjuvant Chemoimmunotherapy for HPV Negative Resectable Locally Advanced HNSCC
NCT05459415Squamous Cell Carcinoma of Head and Neck, Neoadjuvant Therapy, Resection Margin
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Not applicable
54
Wuhan
2022-06-22
Active, closed
Phase II Neoadjuvant Pyrotinib Combined With Neoadjuvant Chemotherapy in HER2-low-expressing and HR Positive Early or Locally Advanced Breast Cancer: a Single-arm, Non-randomized, Single-center, Open Label Trial
NCT05165225Breast Cancer, HER2-low-expressing Breast Cancer, Hormone Receptor-positive Breast Cancer, Neoadjuvant Therapy
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2
48
Guangzhou
2021-07-13
Recruiting
Multi-points and Full-thickness Biopsy in the Diagnosis of cCR After Neoadjuvant Therapy for Rectal Cancer
NCT04743102Rectal Cancer, Neoadjuvant Therapy, Complete Remission, Metastasis
Beijing Chao Yang Hospital
Not applicable
260
Beijing
2021-01-01
Active, closed
Toripalimab Combined With Gemcitabine and Cisplatin Treating Resectable Locally Advanced HNSCC
NCT04947241Locally Advanced Head and Neck Squamous Cell Carcinoma, Neoadjuvant Therapy
Fifth Affiliated Hospital, Sun Yat-Sen University
Phase 1
20
Zhuhai
2020-12-15
Active, closed
Carrelizumab, Chemotherapy and Apatinib in the Neoadjuvant Treatment of Resectable Esophageal Squamous Cell Carcinoma
NCT04666090Esophageal Squamous Cell Carcinoma, Neoadjuvant Therapy
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
42
Hangzhou
2020-11-23
Recruiting
Neoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate Cancer
NCT05406999Neoadjuvant Therapy, High Risk Prostate Cancer, Locally Advanced Prostate Cancer, Intense Endocrine Therapy
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 2
900
Nanjing
2020-02-01
Recruiting
Neoadjuvant Toripalimab With or Without Celecoxib in dMMR/MSI-H Colorectal Cancer
NCT03926338Colorectal Cancer, Mismatch Repair-deficient (dMMR), Microsatellite Instability-high (MSI-H), Neoadjuvant Therapy
Sun Yat-sen University
Phase 2
270
Guangzhou
2019-05-10
Rows per page Showing 1–74 of 74
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-china/condition/neoadjuvant-therapy

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 74 of those studies listing the condition Neoadjuvant Therapy.

How many Neoadjuvant Therapy trials are recruiting in China?

38 of the 74 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 21 have not yet opened recruitment, 13 are active but closed to new participants, and 2 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Neoadjuvant Therapy), 74 studies
PhaseStudiesRecruitingShare
Phase 2441959.5%
Observational9812.2%
Not applicable8310.8%
Phase 3658.1%
Phase 1212.7%
Phase 2/3212.7%
Phase 4212.7%
Phase 1/2101.4%

Most active sponsors

Lead sponsors with the most studies (Neoadjuvant Therapy)
Lead sponsorStudiesRecruiting
Fudan University64
Sun Yat-sen University65
Second Affiliated Hospital, Zhejiang University, School of Medicine50
Cancer Institute and Hospital, Chinese Academy of Medical Sciences31
Peking University People's Hospital33
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology31
First Affiliated Hospital of Guangxi Medical University20
Fujian Medical University Union Hospital20
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine21
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University21
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.